Megat Abd Hamid
Postdoctoral Research Scientist
DPhil; B.Biotech (Hons)
My research focus is on understanding the characteristics and underlying mechanisms of co-inhibitory and co-stimulatory receptors on cancer-specific cytotoxic T cells and how this could be manipulated for future cancer immunotherapies. Primarily, I am looking into:
1. Distribution of HLA-E and its inhibitory receptors CD94/NKG2a and exploitation of this machinery by cancer to inhibit anti-tumor T cell responses.
2. Importance of self-sustain, highly energetic CD103+ tissue resident memory T cells in anti-tumor responses
3. Epigenetic regulation of effector cytokine responses of cancer-specific T cells.
Self-Maintaining CD103+ Cancer-Specific T Cells Are Highly Energetic with Rapid Cytotoxic and Effector Responses.
Abd Hamid M. et al, (2020), Cancer Immunol Res, 8, 203 - 216
Defective Interferon Gamma Production by Tumor-Specific CD8+ T Cells Is Associated With 5'Methylcytosine-Guanine Hypermethylation of Interferon Gamma Promoter.
Abd Hamid M. et al, (2020), Front Immunol, 11
Enriched HLA-E and CD94/NKG2A Interaction Limits Antitumor CD8+ Tumor-Infiltrating T Lymphocyte Responses.
Abd Hamid M. et al, (2019), Cancer Immunol Res, 7, 1293 - 1306
Unexpected involvement of IL-13 signalling via a STAT6 independent mechanism during murine IgG2a development following viral vaccination.
Hamid MA. et al, (2018), Eur J Immunol, 48, 1153 - 1163